Data Snack | May 2023

Endocrinologist Perspectives: Oral and Injectable Therapies

dQ&A conducted another wave of our Endocrinologist Perspectives research with n=190 endocrinologists across private offices, hospitals, community clinics, and managed care organizations.

Results indicated that:

  • Nearly all Endos (96%) prescribe GLP-1s to their patients with type 2 diabetes and 85% have had an increase in prescription frequency over the past year
  • 94% of Endos prescribe SGLT-2s to their T2 patients and 76% have had an increase in prescription frequency over the past year

From patient research, we know that there can be hesitation to start on insulin. This is reinforced by what Endos see in their offices. Most (86%) receive pushback at least some of the time when asking T2 PWDs to start on basal insulin and 69% agree that the use of these therapies has had an impact on the number of T2 patients using basal insulin.

We’ll be interested to see how these therapies impact insulin usage in T2 patients moving forward, particularly as insulin accessibility improves. Ultimately, dQ&A will continue to track the experience of both patients and healthcare professionals to ensure our clients are able to optimize their business strategy and deliver the best possible care to people with diabetes.

To gain the crucial context our Endocrinologist Perspectives research service offers on everything from orals and injectables to CGMs and smart pens, send us an email at

About dQ&A – The Diabetes Research Company

dQ&A is a social enterprise committed to making life better for people with diabetes. We harness patient voices to drive better business results and better health outcomes. For over 14 years, we have been comprehensively tracking the diabetes experience in the United States, Canada, and Europe. We are trusted by diabetes industry leaders for our independence, commitment, and expertise. Our team has decades of experience in quantitative and qualitative research with a deep knowledge of diabetes. We’re efficient and effective; our insights are actionable and accessible. To learn more, send us an email at For research highlights, visit us at and follow us on LinkedIn (dQ&A – The Diabetes Research Company)